The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC</th>
<th>Lot Number</th>
<th>Expiration Date on Box</th>
<th>Genentech Distribution Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xolair® (omalizumab) 150mg/1mL prefilled syringe (PFS)</td>
<td>50242-215-01</td>
<td>3342758, 3352759</td>
<td>Aug 2021</td>
<td>8/05/2020 – 2/23/2021</td>
</tr>
</tbody>
</table>

Genentech is conducting a limited recall of this product with knowledge of the U. S. Food and Drug Administration. This recall will include communications to appropriate patients. Patient outreach will be conducted by the patient's healthcare provider/prescriber. Patients will be instructed to contact their physicians before making any changes to their therapy. Genentech is conducting this recall because routine testing showed that Xolair PFS from these two lots have an expiration period shorter than expected.